New gene therapy technique for Parkinson's

According to a new study a novel gene therapy technique is safe and may be effective at staving off the worsening symptoms of Parkinson's disease.

Parkinson's is a movement disorder caused by a progressive depletion of the brain chemical dopamine in the area of the brain which controls movement.

The patients in the study were in the advanced stages of the illness and were no longer responding to medicines when they signed up for the experimental therapy.

The study involved a woman and 11 men who received a surgical infusion of fluid containing a viral vector and genes for a protein called GAD (glutamic acid decarboxylase) which is an enzyme critical in controlling a neurotransmitter called GABA.

In Parkinson's, GABA is reduced in the brain which causes a hyper-reactive circuit.

Brain scans taken before, during and after the treatment showed that the brain re-worked the abnormal circuits and patients showed a 27 percent improvement in symptoms.

They found that the gene therapy had no adverse side effects and reduced the symptoms of Parkinson's disease with benefits lasting for up to 4 years.

The study found that though the gene therapy could be used to reduce symptoms it did not alter the underlying disease process.

The study was conducted by Dr. Andrew Feigin, director of Neuroscience Experimental Therapeutics at The Feinstein Institute for Medical Research in collaboration with Parkinson's scientists at New York Presbyterian Hospital-Weill Cornell Medical Center in Manhattan.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Promising gene editing therapy shows hope in sickle cell disease cure